Essential technologies for characterising stability of protein based vaccines

30 Mar, 2020 | Newsletters
Essential technologies for characterising stability of protein based vaccines
Since the recent outbreak of the COVID-19 pandemic, Australian scientists together with colleagues around the world, have been working around the clock to speed up the development of a vaccine. We aim to support research in pursuit of accelerating drug discovery and development with access to the latest technologies and expertise.

Differential scanning calorimetry (DSC) is a powerful technique which can used to understand and predict the stability of a potential SARS CoV2 vaccine formulation. 

DSC is considered the “gold standard” thermal stability assay. It provides valuable insights into protein stability, an important indicator of whether a drug will remain functional during formulation and storage without chemical alteration or aggregation, which can give rise to immunogenic responses and in some cases patient death.

  Selecting the most reliable DSC system to assess protein stability
DOWNLOAD THIS GUIDE HERE :This white paper addresses some of the key questions for DSC and compares sensitivity and reproducibility of data to traditional spectroscopic techniques.   

Watch this Webinar : This webinar will describe the use of Differential Scanning Calorimetry (DSC) and Nanoparticle Tracking Analysis (NTA) to understand and predict the stability of vaccine formulations.   

Watch this Webinar: This study provides further detail into the physicochemical characteristics of an antigen as a vaccine candidate and deepens our understanding of its design limits.

Click here to view more webinars focused on Vaccine development

MicroCal PEAQ-DSC is highly sensitive, simple to use, requires little assay development and no labelling or immobilisation. Able to measure verytight binding constants (up to 1020M-1 ), integrated software with automated data analysis supports the generation of non-subjective, highly reproducible data. 
NanoSight NS300 with advanced Nanoparticle Tracking Analysis (NTA) allows high resolution size and count of viral particles. Number-based particle concentration can replace plaque assays while subunit vaccines and other protein based therapeutics can be closely monitored for aggregation.

Click here for a quote today!